Shorla Oncology Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHORLA ONCOLOGY
SHORLA ONCOLOGY has one approved drug.
There is one US patent protecting SHORLA ONCOLOGY drugs.
Summary for Shorla Oncology
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Shorla Oncology
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shorla Oncology | IMKELDI | imatinib mesylate | SOLUTION;ORAL | 219097-001 | Nov 22, 2024 | RX | Yes | Yes | 11,957,681 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shorla Oncology Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3658190 | ⤷ Start Trial |
| Singapore | 11202001720R | ⤷ Start Trial |
| China | 111278466 | ⤷ Start Trial |
| Russian Federation | 2020108342 | ⤷ Start Trial |
| Australia | 2018306149 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shorla Oncology Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0564409 | SPC/GB02/016 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108 |
| 0564409 | 02C0012 | France | ⤷ Start Trial | PRODUCT NAME: IMATINIB MESILATE; NAT. REGISTRATION NO/DATE: EU/1/01/198/001 20011107; FIRST REGISTRATION: LI - IKS 55 807 20010621 |
| 0564409 | C300086 | Netherlands | ⤷ Start Trial | PRODUCT NAME: IMATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESILAAT; NATL. REGISTRATION NO/DATE: EU/1/01/198/001 - 006 20011107; FIRST REGISTRATION: CH IKS 55807 20010621 |
| 0564409 | C00564409/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IMATINIB; REGISTRATION NO/DATE: IKS 55807 20010621 |
| 0564409 | 2002/005 | Ireland | ⤷ Start Trial | PRODUCT NAME: IMATINIB OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; NAT REGISTRATION NO/DATE: EU/1/01/198/001-006 20011107; FIRST REGISTRATION NO/DATE: CH 55807 55807 01 55807 02 20010621; PAEDIATRIC INVESTIGATION PLAN: P/0028/2012 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
